Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  St Germain, Carly ^a,b   O'Brien, Anna ^a,b   Dimitroulakos, Jim ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 4; CISPLATIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; M 344; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; FIBROBLAST; HETEROZYGOTE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; WESTERN BLOTTING;

EID: 77956479878     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-32     Document Type: Article

References (43)

1. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269(1):7-17. 10.1016/j.canlet.2008.03.037, 18462867.
2. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69(14):1911-1934. 10.2165/11315680-000000000-00000, 19747008.
3. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26(37):5541-5552. 10.1038/sj.onc.1210620, 17694093.
4. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009, 107(4):600-608. 10.1002/jcb.22185, 2766855, 19459166.
5. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007, 16(7):1111-1120. 10.1517/13543784.16.7.1111, 17594194.
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7(8):573-584. 10.1038/nrc2167, 17625587.
7. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63(1):12-31. 10.1016/j.critrevonc.2007.02.001, 17336087.
8. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22(47):7265-7279. 10.1038/sj.onc.1206933, 14576837.
9. Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, Yokoi T, Noguchi S. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 2009, 56(2):245-249. 10.1507/endocrj.K08E-016, 19088401.
10. Pauer LR, Olivares J, Cunningham C, Williams A, Grove W, Kraker A, Olson S, Nemunaitis J. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 2004, 22(6):886-896. 10.1081/CNV-200039852, 15641487.
11. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007, 13(12):3605-3610. 10.1158/1078-0432.CCR-07-0162, 17510206.
12. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 2008, 99(2):376-384. 10.1111/j.1349-7006.2007.00669.x, 18201278.
13. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003, 63(21):7291-7300.
14. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009, 15(8):2818-2828. 10.1158/1078-0432.CCR-08-1579, 19351772.
15. Bandyopadhyay K, Baneres JL, Martin A, Blonski C, Parello J, Gjerset RA. Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization. Cell Cycle 2009, 8(17):2779-2788.
16. Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H, Chen Q. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 2007, 73(12):1901-1909. 10.1016/j.bcp.2007.03.009, 17445779.
17. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 2008, 99(6):1218-1226. 10.1111/j.1349-7006.2008.00793.x, 18429963.
18. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007, 30(5):1181-1188.
19. St Germain C, Niknejad N, Ma L, Garbuio K, Hai T, Dimitroulakos J. Cisplatin induces cytotoxicity through the Mitogen-Activated Protein Kinase pathways and activating transcription factor 3. Neoplasia 2010, 12(7):527-538. 2907579, 20651982.
20. Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 2001, 273(1):1-11. 10.1016/S0378-1119(01)00551-0, 11483355.
21. Hsu JC, Laz T, Mohn KL, Taub R. Identification of LRF-1, a leucine-zipper protein that is rapidly and highly induced in regenerating liver. Proc Natl Acad Sci USA 1991, 88(9):3511-3515. 10.1073/pnas.88.9.3511, 51481, 1902565.
22. Chen BP, Wolfgang CD, Hai T. Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10. Mol Cell Biol 1996, 16(3):1157-1168. 231098, 8622660.
23. Yin T, Sandhu G, Wolfgang CD, Burrier A, Webb RL, Rigel DF, Hai T, Whelan J. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 1997, 272(32):19943-19950. 10.1074/jbc.272.32.19943, 9242662.
24. Takeda M, Kato H, Takamiya A, Yoshida A, Kiyama H. Injury-specific expression of activating transcription factor-3 in retinal ganglion cells and its colocalized expression with phosphorylated c-Jun. Invest Ophthalmol Vis Sci 2000, 41(9):2412-2421.
25. Yin X, Dewille JW, Hai T. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 2008, 27(15):2118-2127. 10.1038/sj.onc.1210861, 17952119.
26. Fan W, Jin S, Tong T, Zhao H, Fan F, Antinore MJ, Rajasekaran B, Wu M, Zhan Q. BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J Biol Chem 2002, 277(10):8061-8067. 10.1074/jbc.M110225200, 11777930.
27. Bottone FG, Moon Y, Kim JS, Alston-Mills B, Ishibashi M, Eling TE. The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther 2005, 4(5):693-703. 10.1158/1535-7163.MCT-04-0337, 15897233.
28. Lu D, Wolfgang CD, Hai T. Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 2006, 281(15):10473-10481. 10.1074/jbc.M509278200, 16469745.
29. Zhang C, Gao C, Kawauchi J, Hashimoto Y, Tsuchida N, Kitajima S. Transcriptional activation of the human stress-inducible transcriptional repressor ATF3 gene promoter by p53. Biochem Biophys Res Commun 2002, 297(5):1302-1310. 10.1016/S0006-291X(02)02382-3, 12372430.
30. Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, et al. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res 2006, 66(22):10750-10759. 10.1158/0008-5472.CAN-06-0916, 17108111.
31. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006, 34(Pt 1):7-11.
32. Lu D, Chen J, Hai T. The regulation of ATF3 gene expression by mitogen-activated protein kinases. Biochem J 2007, 401(2):559-567. 10.1042/BJ20061081, 1820813, 17014422.
33. Hamdi M, Popeijus HE, Carlotti F, Janssen JM, van der Burgt C, Cornelissen-Steijger P, van de Water B, Hoeben RC, Matsuo K, van Dam H. ATF3 and Fra1 have opposite functions in JNK- and ERK-dependent DNA damage responses. DNA Repair (Amst) 2008, 7(3):487-496. 10.1016/j.dnarep.2007.12.004, 18249159.
34. Niknejad N, Morley M, Dimitroulakos J. Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem 2007, 282(41):29748-29756. 10.1074/jbc.M705859200, 17699156.
35. Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N, Saisho H. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 2004, 41(3):436-445. 10.1016/j.jhep.2004.05.018, 15336447.
36. Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, Wang X, Ron D, Cavener DR, Wek RC. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 2004, 24(3):1365-1377. 10.1128/MCB.24.3.1365-1377.2004, 321431, 14729979.
37. Wilson AJ, Chueh AC, Togel L, Corner GA, Ahmed N, Goel S, Byun DS, Nasser S, Houston MA, Jhawer M, et al. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 2010, 70(2):609-620. 10.1158/0008-5472.CAN-09-2327, 20068171.
38. Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 2005, 19(9):1579-1589. 10.1038/sj.leu.2403868, 16015388.
39. Kahali S, Sarcar B, Fang B, Williams ES, Koomen JM, Tofilon PJ, Chinnaiyan P. Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia 2010, 12(1):80-86. 2805886, 20072656.
40. Wolfgang CD, Chen BP, Martindale JL, Holbrook NJ, Hai T. gadd153/Chop10, a potential target gene of the transcriptional repressor ATF3. Mol Cell Biol 1997, 17(11):6700-6707. 232524, 9343434.
41. Allan AL, Albanese C, Pestell RG, LaMarre J. Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes. J Biol Chem 2001, 276(29):27272-27280. 10.1074/jbc.M103196200, 11375399.
42. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009, 280(2):125-133. 10.1016/j.canlet.2009.02.042, 19359091.
43. Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 2009, 64(6):1115-1122. 10.1007/s00280-009-0969-x, 19280190.